Serina Therapeutics Net Income
| SER Stock | 2.72 0.02 0.73% |
As of the 29th of January, Serina Therapeutics has the Risk Adjusted Performance of (0.09), variance of 34.18, and Coefficient Of Variation of (707.03). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Serina Therapeutics, as well as the relationship between them. Please validate Serina Therapeutics risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Serina Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 2.72 per share. Please also confirm Serina Therapeutics jensen alpha, which is currently at (0.91) to double-check the company can sustain itself at a future point.
Serina Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Serina Therapeutics' valuation are provided below:Serina Therapeutics does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Can Stock industry sustain growth momentum? Does Serina have expansion opportunities? Factors like these will boost the valuation of Serina Therapeutics. If investors know Serina will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Serina Therapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Serina Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Serina Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Serina Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Serina Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Serina Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Serina Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Serina Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Serina Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Serina Therapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Serina Therapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Serina Therapeutics or generate 0.0% return on investment in Serina Therapeutics over 90 days. Serina Therapeutics is related to or competes with Genenta Science, Skye Bioscience, Jupiter Neurosciences, Aligos Therapeutics, Barinthus Biotherapeutics, INmune Bio, and X4 Pharmaceuticals. More
Serina Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Serina Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Serina Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 23.77 | |||
| Value At Risk | (8.66) | |||
| Potential Upside | 8.95 |
Serina Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Serina Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Serina Therapeutics' standard deviation. In reality, there are many statistical measures that can use Serina Therapeutics historical prices to predict the future Serina Therapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (1.25) | |||
| Treynor Ratio | (0.59) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Serina Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Serina Therapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.58) | |||
| Mean Deviation | 4.3 | |||
| Coefficient Of Variation | (707.03) | |||
| Standard Deviation | 5.85 | |||
| Variance | 34.18 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (1.25) | |||
| Treynor Ratio | (0.59) | |||
| Maximum Drawdown | 23.77 | |||
| Value At Risk | (8.66) | |||
| Potential Upside | 8.95 | |||
| Skewness | 0.6461 | |||
| Kurtosis | 1.07 |
Serina Therapeutics Backtested Returns
Serina Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.14, which indicates the firm had a -0.14 % return per unit of risk over the last 3 months. Serina Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Serina Therapeutics' Risk Adjusted Performance of (0.09), coefficient of variation of (707.03), and Variance of 34.18 to confirm the risk estimate we provide. The entity has a beta of 1.42, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Serina Therapeutics will likely underperform. At this point, Serina Therapeutics has a negative expected return of -0.83%. Please make sure to validate Serina Therapeutics' maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if Serina Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.09 |
Very weak reverse predictability
Serina Therapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Serina Therapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Serina Therapeutics price movement. The serial correlation of -0.09 indicates that less than 9.0% of current Serina Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.09 | |
| Spearman Rank Test | -0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 0.09 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Serina Therapeutics reported net income of (11.21 Million). This is 103.28% lower than that of the Biotechnology sector and 116.0% lower than that of the Health Care industry. The net income for all United States stocks is 101.96% higher than that of the company.
Serina Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Serina Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Serina Therapeutics could also be used in its relative valuation, which is a method of valuing Serina Therapeutics by comparing valuation metrics of similar companies.Serina Therapeutics is currently under evaluation in net income category among its peers.
Serina Fundamentals
| Return On Equity | -4.85 | |||
| Return On Asset | -1.38 | |||
| Operating Margin | (188.69) % | |||
| Current Valuation | 26.64 M | |||
| Shares Outstanding | 10.66 M | |||
| Shares Owned By Insiders | 47.29 % | |||
| Shares Owned By Institutions | 4.35 % | |||
| Number Of Shares Shorted | 85.19 K | |||
| Price To Book | 29.88 X | |||
| Price To Sales | 250.05 X | |||
| Revenue | 56 K | |||
| Gross Profit | (12 M) | |||
| EBITDA | (10.49 M) | |||
| Net Income | (11.21 M) | |||
| Cash And Equivalents | 3.67 M | |||
| Total Debt | 268 K | |||
| Book Value Per Share | (0.30) X | |||
| Cash Flow From Operations | (17.14 M) | |||
| Short Ratio | 0.93 X | |||
| Earnings Per Share | (1.87) X | |||
| Target Price | 13.0 | |||
| Number Of Employees | 12 | |||
| Market Capitalization | 29.01 M | |||
| Total Asset | 6.72 M | |||
| Retained Earnings | (44.32 M) | |||
| Working Capital | 3.31 M | |||
| Net Asset | 6.72 M |
About Serina Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Serina Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Serina Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Serina Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Serina Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Serina Stock
| 0.75 | AA | Alcoa Corp | PairCorr |
| 0.68 | BA | Boeing | PairCorr |
| 0.65 | WMT | Walmart Common Stock | PairCorr |
| 0.64 | MRK | Merck Company Earnings Call This Week | PairCorr |
| 0.55 | RIVN | Rivian Automotive | PairCorr |
The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.